ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

efanesoctocog alfa

Also written as “Efanesoctocog alfa”, “efanesoctocog alfa (BIVV001)” and “BIVV001 (Low Dose)”.

Its studies are mostly in Hemophilia A · von Willebrand Diseases, led by 2 companies.

Drug pageEfanesoctocog alfa: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 16, 202512 company-led studies, 5 open or runningNext primary completion: Nov 17, 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi72 open or runningphase 4since Apr 16, 2025Jun 29, 2017Jan 15, 2027phase 3 · NCT04644575
Swedish Orphan Biovitrumits history only53 open or runningphase 4since Dec 18, 2024Mar 21, 2023Nov 17, 2026phase 4 · NCT06752850

Also a collaborator on its studies: PSI CRO.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 29, 2017First study: phase 2 study in Hemophilia AFirst studyNCT03205163 · 16 enrolled · United States, Japan
  2. Nov 5, 2019Phase 3 study in Hemophilia ANCT04161495 · 159 enrolled · United States, Argentina, Australia and more
  3. Dec 9, 2019Named efanesoctocog alfaINNProposed as its International Nonproprietary Name in WHO's List 122
  4. Nov 23, 2020Phase 3 study in Hemophilia ANCT04644575 · 261 enrolled · United States, Argentina, Australia and more
  5. Feb 13, 2021Phase 3 study in Hemophilia ANCT04759131 · 74 enrolled · United States, Australia, Canada and more
  6. Feb 22, 2021Phase 1 study in von Willebrand DiseasesNCT04770935 · 6 enrolled · United States, France
  7. Aug 12, 2021Phase 1 study in Hemophilia ANCT05042440 · 13 enrolled · Bulgaria
  8. Apr 16, 2025Phase 4 study in Hemophilia ANCT06941870 · 35 planned · United States, Australia, Canada and more

Ahead

  1. Jan 15, 2027Primary completion: phase 3 study in Hemophilia ANCT04644575
  2. Oct 25, 2027Primary completion: phase 4 study in Hemophilia ANCT06941870

TargetBeta

F8 →read by rule
“A recombinant fusion protein comprising a single chain B-domain deleted (BDD) analog of human antihemophilic factor (coagulation factor VIII; FVIII) covalently ”NCIt, by rule
“Coagulation factor VIII exogenous protein”ChEMBL 37, by rule

Other programs on F8

ProgramCompanyFurthest phaseStudies
antihemophilic factor, human recombinantruleTakedaphase 416
omfiloctocog alfaruleSinocelltech Groupphase 46
lonoctocog alfaruleCSLphase 34

Studies

All 7 Sanofi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06941870Hemophilia A · United States, Australia, Canada and more4RecruitingOct 25, 202735
NCT05042440Hemophilia A · Bulgaria1CompletedNov 24, 202113
NCT04770935von Willebrand Diseases · United States, France1CompletedDec 1, 20226
NCT04759131Hemophilia A · United States, Australia, Canada and more3CompletedJan 18, 202374
NCT04644575Hemophilia A · United States, Argentina, Australia and more3Active, not recruitingJan 15, 2027261
NCT04161495Hemophilia A · United States, Argentina, Australia and more3CompletedFeb 3, 2022159
NCT03205163Hemophilia A · United States, Japan2CompletedNov 12, 201816

How it is read

Names in the registry

  • “Efanesoctocog alfa”, 7 entries
  • “efanesoctocog alfa (BIVV001)”, 4 entries
  • “BIVV001 (Low Dose)”, 1 entry
  • “BIVV001 (High Dose)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.